Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 4/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.42 |
| ▸ | TUBB | P07437 | 1/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19808909 | 0.91 | TUBB4A (0.51) | P2RX3L3MBTL1SMN1; SMN2ALDH1A1EGLN1 | |
| SCHEMBL19808901 | 0.89 | P2RX3 (0.48) | P2RX3L3MBTL1NPC1MAPTNFKB1 | |
| SCHEMBL19808853 | 0.89 | P2RX3 (0.48) | P2RX3L3MBTL1NPC1MAPTRAB9A | |
| SCHEMBL19808862 | 0.88 | TDP1 (0.50) | P2RX3L3MBTL1NPC1MAPTRAB9A | |
| SCHEMBL19808896 | 0.86 | P2RX3 (0.47) | P2RX3L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL19808847 | 0.85 | LMNA (0.55) | P2RX3MAPTALDH1A1EGLN1TUBB4A | |
| SCHEMBL19808837 | 0.85 | P2RX3 (0.48) | P2RX3L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL19994239 | 0.85 | P2RX3 (0.45) | P2RX3L3MBTL1NPC1MAPTRAB9A | |
| SCHEMBL19808829 | 0.83 | L3MBTL1 (0.54) | P2RX3L3MBTL1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL19808864 | 0.81 | P2RX3 (0.43) | P2RX3L3MBTL1NPC1MAPTNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3275881-B1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-10100051-B2 | Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof | SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) | 2018-10-16 | — | — | US | disclosed |
| US-20180118739-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-03 | — | — | US | disclosed |
| EP-3275881-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | Shenyang Sunshine Pharmaceutical Co., Ltd. (CN) | 2018-01-31 | — | — | EP | disclosed |
| EP-1861382-B1 | FUSED AROMATIC COMPOUNDS HAVING ANTI-DIABETIC ACTIVITY | MERCK SHARP & DOHME (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-1861382-B1 | FUSED AROMATIC COMPOUNDS HAVING ANTI-DIABETIC ACTIVITY | MERCK SHARP & DOHME (US) | 2012-10-10 | — | — | EP | disclosed |
| US-8258161-B2 | Crystalline salt form of an antidiabetic compound | MERCK SHARP & DOHME CORP. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258161-B2 | Crystalline salt form of an antidiabetic compound | MERCK SHARP & DOHME CORP. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258161-B2 | Crystalline salt form of an antidiabetic compound | MERCK SHARP & DOHME CORP. (US) | 2012-09-04 | — | — | US | disclosed |
| US-7834036-B2 | Fused-aromatic compounds having anti-diabetic activity | MERCK SHARP & DOHME CORP (US) | 2010-11-16 | — | — | US | disclosed |
| WO-2008109334-A1 | NOVEL CRYSTALLINE SALT FORM OF AN ANTIDIABETIC COMPOUND | MERCK & CO., INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080194586-A1 | Fused-Aromatic Compounds Having Anti-Diabetic Activity | MERCK SHARP & DOHME LLC | 2008-08-14 | — | — | US | disclosed |
| US-20080194586-A1 | Fused-Aromatic Compounds Having Anti-Diabetic Activity | MERCK SHARP & DOHME LLC | 2008-08-14 | — | — | US | disclosed |
| US-20080194586-A1 | Fused-Aromatic Compounds Having Anti-Diabetic Activity | MERCK SHARP & DOHME LLC | 2008-08-14 | — | — | US | disclosed |
| EP-1909789-A2 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | Merck & Co., Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1861382-A1 | FUSED AROMATIC COMPOUNDS HAVING ANTI-DIABETIC ACTIVITY | Merck & Co., Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007103252-A2 | NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007103252-A2 | NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007018956-A2 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO., INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2006096564-A1 | FUSED AROMATIC COMPOUNDS HAVING ANTI-DIABETIC ACTIVITY | MERCK & CO., INC. (US) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118739-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | HIF1AN, EGLN3, EGLN2 | P2RX3 1425/4885L3MBTL1 4819/4885NPC1 991/4885 |
| US-20080194586-A1 | Fused-Aromatic Compounds Having Anti-Diabetic Activity | PPARG, PPARA, FABP4 | P2RX3 3392/4885L3MBTL1 2202/4885NPC1 390/4885 |
| US-10100051-B2 | Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof | HIF1AN, EGLN3, EGLN2 | P2RX3 1425/4885L3MBTL1 4819/4885NPC1 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.